环孢素或英夫利西单抗治疗激素难治性急性重度溃疡性结肠炎的长期结局
该随机试验纳入115例激素难治性急性重度溃疡性结肠炎患者,在欧洲29个中心随机接受环孢素或英夫利西单抗联合硫唑嘌呤治疗。中位随访5.4年,两组1年和5年无结肠切除生存率无显著差异(p=0.97),长期无结肠切除生存与初始治疗无关。
要点
- 激素难治性急性重度溃疡性结肠炎患者中,环孢素与英夫利西单抗的长期无结肠切除生存率无显著差异。
- 环孢素组1年和5年无结肠切除生存率分别为70.9%和61.5%,英夫利西单抗组分别为69.1%和65.1%(p=0.97)。
- 初始环孢素治疗患者中,1年和5年首次使用英夫利西单抗的累积发生率分别为45.7%和57.1%。
核心结论
- 在初始接受环孢素或英夫利西单抗治疗的激素难治性急性重度溃疡性结肠炎患者队列中,长期无结肠切除生存与初始治疗无关。
- 这些长期结果进一步证实两种药物疗效相似且安全性良好,不倾向于其中任何一种药物。
研究设计与样本
- 2007年至2010年间,115例激素难治性急性重度溃疡性结肠炎患者在29个欧洲中心被随机分配接受环孢素或英夫利西单抗联合硫唑嘌呤治疗。
- 随访至死亡或最后消息,截至2015年1月。
- 通过Kaplan-Meier法估计1年和5年无结肠切除生存率及治疗变化,并通过log-rank检验比较初始治疗组间的差异。
主要发现
- 中位随访5.4年,环孢素组1年和5年无结肠切除生存率(95%CI)分别为70.9%(59.2%至82.6%)和61.5%(48.7%至74.2%),英夫利西单抗组分别为69.1%(56.9%至81.3%)和65.1%(52.4%至77.8%)(p=0.97)。
- 初始接受环孢素治疗的患者中,1年和5年首次使用英夫利西单抗的累积发生率分别为45.7%(32.6%至57.9%)和57.1%(43.0%至69.0%)。
- 英夫利西单抗组仅有4例患者随后转换为环孢素。
- 随访期间有3例患者死亡,均与溃疡性结肠炎或其治疗无直接关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Ciclosporin and infliximab have demonstrated short-term similar efficacy as second-line therapies in patients with acute severe UC (ASUC) refractory to intravenous steroids. The aim of this study was to assess long-term outcome of patients included in a randomised trial comparing ciclosporin and infliximab. DESIGN: Between 2007 and 2010, 115 patients with steroid-refractory ASUC were randomised in 29 European centres to receive ciclosporin or infliximab in association with azathioprine. Patients were followed until death or last news up to January 2015. Colectomy-free survival rates at 1 and 5 years and changes in therapy were estimated through Kaplan-Meier method and compared between initial treatment groups through log-rank test. RESULTS: After a median follow-up of 5.4 years, colectomy-free survival rates (95% CI) at 1 and 5 years were, respectively, 70.9% (59.2% to 82.6%) and 61.5% (48.7% to 74.2%) in patients who received ciclosporin and 69.1% (56.9% to 81.3%) and 65.1% (52.4% to 77.8%) in those who received infliximab (p=0.97). Cumulative incidence of first infliximab use at 1 and 5 years in patients initially treated with ciclosporin was, respectively, 45.7% (32.6% to 57.9%) and 57.1% (43.0% to 69.0%). Only four patients from the infliximab group were subsequently switched to ciclosporin. Three patients died during the follow-up, none directly related to UC or its treatment. CONCLUSIONS: In this cohort of patients with steroid-refractory ASUC initially treated by ciclosporin or infliximab, long-term colectomy-free survival was independent from initial treatment. These long-term results further confirm a similar efficacy and good safety profiles of both drugs and do not favour one drug over the other. TRIAL REGISTRATION NUMBER: EudraCT: 2006-005299-42; ClinicalTrials.gouv number: NCT00542152; post-results.
引用
- Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut. 2017. PMID: 28053054. doi:10.1136/gutjnl-2016-313060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。